Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis

• ClinicalTrials.gov Identifier: NCT06042647
• Recruitment Status: Completed
• First Posted: September 18, 2023
• Last Update Posted: November 18, 2023
• Sponsor: Dermatology Consulting Services, PLLC
• Information provided by (Responsible Party): Dermatology Consulting Services, PLLC

Study Description

Brief Summary:

The objective of this research is to demonstrate superior anti-inflammatory effects, as demonstrated by a reduction in TNF-a and IL-17A, with tazarotene/halobetasol lotion in patients with mild to moderate plaque type psoriasis as compared to clobetasol propionate 0.05% cream.

Condition or disease	Intervention/treatment	Phase
Psoriasis Vulgaris	Drug: 0.01% Halobetasol; Drug: 0.045% Tazarotene; Drug: 0.05% Clobetasol Propionate	Phase 4

Detailed Description:

Male or female subjects with mild to moderate plaque type psoriasis will present to the research center for evaluation for study entry. They will have been advised to present to the research center with clean skin and no topical products applied to the body, including medications, moisturizers, sunscreens, etc. If found to be suitable by meeting all inclusion criteria and none of the exclusion criteria, subjects will undergo selection of 2 target plaques by the dermatologist investigator. Each plaque will be graded for erythema, scaling, and induration. An Investigational Global Assessment (IGA) score will be assigned for each plaque. Plaques must have an IGA of mild (2) or moderate (3) to qualify for inclusion. The subjects will also assess each plaque for redness, thickness, and scaling. Each of the plaques will be photographed.The subjects will undergo D-squame tape strip removal of each of the 2 target psoriasis plaques. One plaque will serve as the tazarotene/halobetasol lotion treated plaque and the other will serve as the clobetasol propionate 0.05% cream treated plaque. 10 D-squames will be obtained with from each plaque. 5 tape strips will be placed in each glass jar. One jar will contain the even tape strips and the other jar will contain the odd tape strips. 10 D-squames will also be taken from normal skin to serve as a negative control in an individual without psoriasis. 5 tape strips will be placed in each glass jar. One jar will contain the even tape strips and the other jar will contain the odd tape strips. The D-squames will be frozen in a -80C freezer for later assessment. Five tape strips will be analyzed together to obtain adequate material for ELISA analysis. Two specimens jars will be prepared for from each of the 2 target plaques. One jar will be analyzed with the second jar serving as a back up.The subjects will have a number assigned to each of the treatment plaques. The numbers will be recorded on a body map. Two copies will be prepared. One copy will remain at the research center and the second copy will be provided to the subject. Each subject will receive one tube of tazarotene/halobetasol lotion for application to one randomized target plaque and a tube of clobetasol propionate 0.05% cream to apply the second randomized target plaque.Subjects will be provided with a diary. They will be instructed to apply the study product at bedtime to the designated target plaque. Care must be taken to apply the proper product to the proper plaque. Subjects will be instructed to return to the research center in 4 weeks. A reminder text for compliance will be provided prior to the week 4 visit.Subjects will return to the research center at week 4. The dermatologist investigator will evaluate each plaque for erythema, scaling, and induration. An Investigational Global Assessment (IGA) score will be assigned for each plaque. The subjects will also assess each plaque for redness, thickness, and scaling. Each of the plaques will be photographed. The subjects will undergo D-squame tape strip removal of 10 tape strips for each of the 2 target psoriasis plaques. Five tape strips will be placed in each jar with one jar receiving the even tape strips and the other jar receiving the odd tape strips. The D-squames will be frozen in a -80C freezer for later assessment. Subjects will discontinue treatment of the plaques at this time. All medication and study diaries will be collected. Subjects will be asked to return to the research center at week 8. A reminder text for compliance will be sent prior to the week 8 visit.Subjects will return to the research center at week 8. No treatment will be applied to the target plaques for the past 4 weeks. The dermatologist investigator will evaluate each plaque for erythema, scaling, and induration. An Investigational Global Assessment (IGA) score will be assigned for each plaque. The subjects will also assess each plaque for redness, thickness, and scaling. Each of the plaques will be photographed. The subjects will undergo D-squame tape strip removal 10 times for each of the 2 target psoriasis plaques. Five tape strips will be placed in each jar with one jar containing the even tape strips and the other jar containing the odd tape strips. The D-squames will be frozen in a -80C freezer for later assessment. Subjects will complete their study participation at this time.The D-squames will be analyzed using ELISA for the amount of TNF-a and IL-17A present after 4 weeks of treatment with tazarotene/halobetasol lotion to one randomized target plaque and clobetasol propionate 0.05% cream to apply the second randomized target plaque. Treatment will be discontinued at week 4 and subjects will remain untreated for the subsequent 4 weeks. At week 8, D-squames will be analyzed using ELISA for the amount of TNF-a and IL-17A present after 4 weeks off treatment with tazarotene/halobetasol lotion to one randomized target plaque and clobetasol propionate 0.05% cream to apply the second randomized target plaque. This research will allow comparison between a retinoid/topical corticosteroid combination and a topical corticosteroid alone in terms of inflammatory mediator reduction. It will also provide insight into the ability of a retinoid/topical corticosteroid combination to produce longer lasting inflammatory mediator reduction than a topical corticosteroid alone.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 10 participants
• Allocation: Non-Randomized
• Intervention Model: Single Group Assignment
• Intervention Model Description: One product applied to psoriasis on the right side of the body and a second product applied to the left side of the body. The right and left side product applications will be randomized.
• Masking: Single (Investigator)
• Masking Description: Investigator will not know which product is applied to the right and left psoriasis target plaque.
• Primary Purpose: Treatment
• Official Title: A Demonstration of the Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion as Compared to 0.05% Clobetasol Propionate Cream in the Treatment of Psoriasis
• Actual Study Start Date: July 13, 2023
• Actual Primary Completion Date: November 13, 2023
• Actual Study Completion Date: November 13, 2023

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: 0.01% Halobetasol and 0.045% Tazarotene Lotion; 0.01% Halobetasol and 0.045% Tazarotene Lotion (Duobrii)Applied to designated target plaque at bedtime.	Drug: 0.01% Halobetasol; Drug to be applied at bedtime to designated target psoriasis plaque at bedtime.; Drug: 0.045% Tazarotene; Drug to be applied in combination with 0.01% Halobetasol to the designated psoriasis plaque at bedtime.
Active Comparator: Clobetasol Propionate 0.05% Cream (generic); Clobetasol Propionate 0.05% Cream (generic)Applied to designated target plaque at bedtime.	Drug: 0.05% Clobetasol Propionate; Drug to be applied to designated psoriatic plaque at bedtime.

Outcome Measures

Primary Outcome Measures :

1. Concentration of TNF-a and IL-17A in Psoriatic Plaques [ Time Frame: 8 weeks ]
   The primary outcome is to compare the concentration of TNF-a and/or IL-17A after discontinuing treatment for 4 weeks with tazarotene/halobetasol lotion as compared to clobetasol propionate 0.05% cream.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

1. Males or non-pregnant females 18+ years of age.
2. Plaque type mild to moderate psoriasis suitable for topical treatment.
3. The presence of 2 plaques suitable for tape stripping
4. Subjects must be willing to allow a series of tape pieces to be pressed and removed from 2 target psoriasis plaques.
5. Subjects must be in general good health as determined from a medical history.
6. Subjects must read and sign the informed consent form after the nature of the study has been fully explained.

Exclusion Criteria:

1. Subjects with known allergies or sensitivities to ingredients contained in the test products.
2. Subjects with an allergy to latex or adhesives.
3. Subjects with pustular or erythrodermic psoriasis.
4. Subjects who are pregnant or nursing or planning to become pregnant during the course of the study.
5. Subjects who are currently participating in any other clinical study (i.e., dermal patch, use tests, investigational drug or devices, etc.).
6. Subjects viewed by the investigator as not being able to complete the study.
7. Subjects using any type of lotion, medication, or other topical product to the psoriasis plaques.

Contacts and Locations

Locations

United States, North Carolina

Dermatology Consulting Services, PLLC

High Point, North Carolina, United States, 27262

Sponsors and Collaborators

Dermatology Consulting Services, PLLC

More Information

• Responsible Party: Dermatology Consulting Services, PLLC
• ClinicalTrials.gov Identifier: NCT06042647
• Other Study ID Numbers: DCS-69-22
• First Posted: September 18, 2023
• Last Update Posted: November 18, 2023
• Last Verified: November 2023

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:

Psoriasis; Skin Diseases, Papulosquamous; Skin Diseases; Clobetasol; Halobetasol; Tazarotene; Anti-Inflammatory Agents; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Physiological Effects of Drugs; Dermatologic Agents; Keratolytic Agents; Vasoconstrictor Agents